[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse RGS9

Summary
SymbolRGS9
Nameregulator of G-protein signaling 9
Aliases RGS9L; MGC26458; MGC111763; regulator of G protein signalling 9; regulator of G protein signalling 9L; regul ......
Chromosomal Location17q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 3: Membrane; Peripheral membrane protein. Note=Isoform 3 is targeted to the membrane via its interaction with RGS9BP.
Domain PF00610 Domain found in Dishevelled
PF00631 GGL domain
PF00615 Regulator of G protein signaling domain
Function

Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits thereby driving them into their inactive GDP-bound form. Binds to GNAT1. Involved in phototransduction; key element in the recovery phase of visual transduction (By similarity).

> Gene Ontology
 
Biological Process GO:0006457 protein folding
GO:0007212 dopamine receptor signaling pathway
GO:0007601 visual perception
GO:0008277 regulation of G-protein coupled receptor protein signaling pathway
GO:0043627 response to estrogen
GO:0050953 sensory perception of light stimulus
Molecular Function GO:0005096 GTPase activator activity
GO:0008047 enzyme activator activity
GO:0030695 GTPase regulator activity
GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component GO:0001750 photoreceptor outer segment
GO:0001917 photoreceptor inner segment
GO:0005834 heterotrimeric G-protein complex
GO:0005929 cilium
GO:0009898 cytoplasmic side of plasma membrane
GO:0019897 extrinsic component of plasma membrane
GO:0019898 extrinsic component of membrane
GO:0031234 extrinsic component of cytoplasmic side of plasma membrane
GO:0031253 cell projection membrane
GO:0031513 nonmotile primary cilium
GO:0044441 ciliary part
GO:0060170 ciliary membrane
GO:0072372 primary cilium
GO:0097381 photoreceptor disc membrane
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
GO:1905360 GTPase complex
> KEGG and Reactome Pathway
 
KEGG hsa04744 Phototransduction
Reactome R-HSA-390466: Chaperonin-mediated protein folding
R-HSA-6814122: Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-2514859: Inactivation, recovery and regulation of the phototransduction cascade
R-HSA-392499: Metabolism of proteins
R-HSA-391251: Protein folding
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-2514856: The phototransduction cascade
R-HSA-2187338: Visual phototransduction
Summary
SymbolRGS9
Nameregulator of G-protein signaling 9
Aliases RGS9L; MGC26458; MGC111763; regulator of G protein signalling 9; regulator of G protein signalling 9L; regul ......
Chromosomal Location17q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RGS9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolRGS9
Nameregulator of G-protein signaling 9
Aliases RGS9L; MGC26458; MGC111763; regulator of G protein signalling 9; regulator of G protein signalling 9L; regul ......
Chromosomal Location17q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RGS9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRGS9
Nameregulator of G-protein signaling 9
Aliases RGS9L; MGC26458; MGC111763; regulator of G protein signalling 9; regulator of G protein signalling 9L; regul ......
Chromosomal Location17q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RGS9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0930.678
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4040.361
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1360.705
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4620.187
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6510.568
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2260.866
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.2050.0381
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.50.0923
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.9110.341
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2490.808
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2580.849
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.190.272
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RGS9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRGS9
Nameregulator of G-protein signaling 9
Aliases RGS9L; MGC26458; MGC111763; regulator of G protein signalling 9; regulator of G protein signalling 9L; regul ......
Chromosomal Location17q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RGS9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRGS9
Nameregulator of G-protein signaling 9
Aliases RGS9L; MGC26458; MGC111763; regulator of G protein signalling 9; regulator of G protein signalling 9L; regul ......
Chromosomal Location17q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RGS9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RGS9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRGS9
Nameregulator of G-protein signaling 9
Aliases RGS9L; MGC26458; MGC111763; regulator of G protein signalling 9; regulator of G protein signalling 9L; regul ......
Chromosomal Location17q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RGS9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRGS9
Nameregulator of G-protein signaling 9
Aliases RGS9L; MGC26458; MGC111763; regulator of G protein signalling 9; regulator of G protein signalling 9L; regul ......
Chromosomal Location17q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RGS9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRGS9
Nameregulator of G-protein signaling 9
Aliases RGS9L; MGC26458; MGC111763; regulator of G protein signalling 9; regulator of G protein signalling 9L; regul ......
Chromosomal Location17q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RGS9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRGS9
Nameregulator of G-protein signaling 9
Aliases RGS9L; MGC26458; MGC111763; regulator of G protein signalling 9; regulator of G protein signalling 9L; regul ......
Chromosomal Location17q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RGS9 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.